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Abstract
Objective: Duchenne muscular dystrophy is the commonest genetic myopathy but there exist a large number 
of inherited neuromuscular diseases which individually are very rare and where clinical information is not widely 
available. This review is based on the author’s experience in a pediatric muscle clinic and provides practical 
guidance and treatment plans for frequently encountered problems.
Sources: A MEDLINE search was conducted to retrieve recent articles relevant to the management of 
children with inherited myopathies and neuropathies. A patient cohort (n = 200) was evaluated using descriptive 
statistics.
Summary of the findings: Duchenne muscular dystrophy accounted for almost half of the diagnoses, 
followed by spinal muscular atrophy (12%), Becker muscular dystrophy and myotonic dystrophy (7% each). 
Sixteen patients (9%) had an unknown myopathy.
Conclusions: As with other chronic illnesses, these patients should be regularly reviewed by health 
professionals from an early age to increase life expectancy and improve quality of life. It is useful for physicians 
to take a structured approach when looking after children with neuromuscular disorders and to monitor all 
affected organ systems.
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Introduction
Inherited neuromuscular disorders (NMDs) affect 
approximately one in 3,500 children worldwide, and X-
linked Duchenne muscular dystrophy (DMD) has the highest 
incidence among them. Many conditions present with muscle 
weakness and wasting and can be diagnosed by genetic 
mutation analysis alone, but muscle, skin or nerve biopsy 
still remain important diagnostic tools. Although various 
strategies for genetic therapies of these diseases are 
being explored, the cornerstones of current treatment are 
symptomatic and supportive healthcare.1,2 Comprehensive 
reviews on specific NMDs have been published but it can 
be a challenge for the novice or the busy clinician to keep 
up to date with the latest literature when looking after 
children suffering from a wide range of rare disorders.3-5 
However, when monitoring these chronically ill patients 
over a prolonged period, certain recurring themes can 
be observed that are pertinent to most NMDs. These 
themes can be ascribed to the specific muscle or nerve 
pathology and its effect on other systems of the body. 
Here, the author describes his experience of following up 
200 children presenting to a pediatric muscle clinic during 
a 3-year period.
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Disease n (%)
Duchenne muscular dystrophy 77 (45)
Spinal muscular atrophy 21 (12)
Unknown myopathy 16 (9)
Becker muscular dystrophy 12 (7)
Myotonic dystrophy 11 (7)
Merosin-negative congenital muscular dystrophy 5 (3)
Bethlem myopathy 4 (2)
Central core disease 4 (2)
Charcot-Marie-Tooth disease 4 (2)
Nemaline myopathy 3 (2)
Ullrich congenital muscular dystrophy 3 (2)
Facioscapulohumeral muscular dystrophy 2 (1)
Fukuyama congenital muscular dystrophy 2 (1)
Walker-Warburg syndrome 2 (1)
Autosomal recessive limb girdle muscular dystrophy 1 (1)
Myotubular myopathy 1 (1)
Rigid spine muscular dystrophy 1 (1)
X-linked myopathy with excessive autophagy 1 (1)
Table 1 - Spectrum of neuromuscular diseases encountered in a pediatric muscle clinic (n = 170)
Figure 1 - Age distribution of 200 children with neuromuscular 
conditions
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Clinics
The young patients were reviewed on average twice a 
year by a multidisciplinary team consisting of three to five 
doctors (at least one of them senior), one to three specialist 
physiotherapists, two pediatric nurses, one genetic counselor 
and one social care advisor. A psychologist would have been 
desirable but was not routinely available. To reduce travelling 
for the families, one of the appointments was scheduled 
at the regional genetics center and the other at a district 
general hospital close to their homes. This meant that the 
pediatric muscle team held regular outreach clinics covering 
on average 100 miles in a day. The age of the predominantly 
male patients ranged from 1.9 to 19.8 years with a mean 
age of 11.5 years (Figure 1). The children comprised 44% 
of all young patients reviewed during that period, and only 
a small proportion was seen by the author twice. Almost 
half of the patients (45%) had DMD, followed by spinal 
muscular atrophy (SMA), Becker muscular dystrophy (BMD) 
and congenital myotonic dystrophy (MD). A relatively large 
proportion of children (9%) had an unknown myopathy where 
a specific diagnosis had not been reached despite extensive 
investigations. In some cases, a diagnosis was made after 
several years in the light of new research findings. Hospital 
database entries were incomplete for 30 patients (15%). 
The remaining 170 patients presented with 18 different 
diagnoses (Table 1).
Systems
Muscular
At each 1-hour assessment a detailed medical history with 
emphasis on mobility covering the preceding months was 
obtained, and any concerns raised by the parent/caregiver 
or patient were addressed. Muscle strength was measured 
using the Medical Research Council grading: 1 = flicker or 
trace of contraction, 2 = active movement with gravity 
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eliminated, 3 = active movement against gravity, 4 = active 
movement against gravity and resistance, 5 = normal power. 
As a minimum timed tests for rising from the floor, running 
10 m and climbing four stairs up and down were performed 
on all ambulant children. Boys with DMD also underwent a 
North Star Ambulatory Assessment which measures levels 
of activity and gives a maximum score of 34.6 Non-ambulant 
children were assessed using the Egen Classification Scale 
Version 2.7 Most children received regular physiotherapy, 
and their parents were reminded of the importance of daily 
home stretching exercises to prevent contractures. Physical 
activity that was highly competitive or carried an increased 
risk of injury was not recommended. If ankle dorsiflexion 
was not possible beyond the neutral position, night splints 
were prescribed for ambulant children and day splints for 
those in wheelchairs. Manual and electric wheelchairs were 
regularly maintained to ensure a comfortable sitting position. 
Some young people with DMD benefitted from a standing 
frame, swivel walker or knee-ankle-foot orthosis (KAFO).8 A 
recent Cochrane review provided evidence that oral steroids 
improve muscle strength and function in DMD for up to 5 
years.9,10 Accordingly, the patients reviewed here were 
treated with prednisolone 0.75 mg/kg/day or deflazacort 
0.9 mg/kg/day, once their gross motor skills had reached a 
plateau or started to decline, which usually coincided with 
admission to primary school (age 4-6 years). The doses 
were starting doses that were not regularly adjusted with 
changes in body weight but were altered depending on 
the clinical picture. The maximum daily dose for either 
drug was 40 mg. The steroid treatment was generally 
well tolerated, and the observed adverse effects included 
increased appetite, weight gain, behavioral problems, 
high blood pressure, stunted growth, osteoporosis, and 
cataracts. Prior to commencing treatment, all patients had a 
blood screen including full blood count, biochemical profile, 
vitamin D level, and varicella antibodies. If appropriate, 
children were immunized against chickenpox. A family 
history of active tuberculosis was a contraindication for 
steroid treatment of DMD. A steroid alert card was issued to 
every child reminding health professionals of the possibility 
of drug-induced adrenal insufficiency. At each clinic visit, 
weight, height, blood pressure, and forced vital capacity 
(FVC) were measured, and urine was tested for glucose, 
protein, and blood. Although no patient with a myasthenic 
syndrome was among this cohort, the therapeutic options 
for these rare disorders affecting the neuromuscular 
junction should be mentioned. Pyridostigmine bromide, 
3,4-diaminopyridine and ephedrine sulphate are effective 
in non-immune congenital myasthenic syndromes, whereas 
acetyl cholinesterase inhibitors, immunosuppressant drugs, 
and thymectomy are the treatment of choice for juvenile 
autoimmune myasthenia gravis.11,12 Recent studies suggest 
a positive effect of oral salbutamol 2 mg thrice daily on 
muscle power in patients with SMA but the drug was not 
routinely used in this group.13,14
Skeletal
Despite regular physiotherapy and preventative splinting, 
joint contractures were frequently observed in children 
with NMDs, and in some they were present from birth (e.g. 
congenital muscular dystrophy). The commonest type was an 
ankle-foot contracture which was treated with serial casting 
or Achilles tendon release by an orthopedic surgeon.15,16 
At each appointment, the patient’s spine was examined for 
abnormal curvatures (hyperlordosis, scoliosis, and kyphosis) 
and vertebral fractures. There was a low threshold for 
requesting spinal X rays or referring to a spinal surgeon for 
a baseline assessment. Conservative treatment of a scoliosis 
included a spinal brace, and in severe cases spinal fixation 
and fusion surgery were performed.17-19 Osteopenia was 
common in boys with DMD, and the added effect of oral 
steroids increased the incidence of osteoporosis and vertebral 
and other fractures.20,21 The bone mineral density of these 
children was measured by dual-energy X-ray absorptiometry 
(DEXA scan) every 2 years. Lately, patients commenced on 
prednisolone or deflazacort were also prescribed the oral 
bisphosphonate risedronate at a dose of approximately 1 
mg/kg once weekly (maximum dose 35 mg once weekly) 
and a combined calcium and vitamin D preparation on 6 
days per week.22,23 DMD patients on steroids diagnosed 
with a fracture were treated as inpatients with intravenous 
infusions of pamidronate. Twice-yearly dental checkups 
were recommended as osteonecrosis of the jaw (ONJ) is 
a recognized complication of bisphosphonate therapy.24,25 
In children with joint hypermobility, heritable disorders of 
connective tissue, such as Ehlers-Danlos syndrome, were 
considered.
Nervous
Cognitive impairment of varying severity and 
neuropsychiatric disorders were frequently seen in patients 
with dystrophinopathies, MD, and other inherited muscle 
diseases.26-28 When assessing young infants, it was important 
to differentiate between those who had poor truncal but 
good limb tone (central hypotonia) and those who were 
floppy and weak (peripheral hypotonia). In children with 
unknown neuropathy or myopathy, neuroradiological studies 
and peripheral neurophysiological tests were sometimes 
helpful. Associated seizures were controlled with standard 
anti-epileptic drugs (e.g. sodium valproate, carbamazepine). 
Therapeutic sleep systems and melatonin 3-6 mg at night 
were prescribed for patients with sleeping difficulties. 
Occasionally, adolescents with MD and excessive daytime 
sleepiness were treated with modafinil 100 mg once or 
twice daily.29,30 Children with MD and those on long-term 
steroids were screened for small cataracts annually by an 
optician or ophthalmologist. Sensorineural deafness was 
rare but has been reported in MD, facioscapulohumeral 
muscular dystrophy, and Charcot-Marie-Tooth disease.31 
Malignant hyperthermia is a serious condition associated 
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with general anesthesia and characterized by muscle 
rigidity, rhabdomyolysis, acidosis, myoglobinuria, and 
hyperthermia. Patients with a wide range of myopathies can 
be affected and they were made aware of this risk prior to 
undergoing surgery.32 When patients complained of pain, 
their symptoms were analyzed according to main site, 
radiation, character, severity, duration, and frequency. In 
young children, a simple pain rating scale was used.33 If an 
underlying pathology could be identified, specific treatment 
was initiated. Leg pain and cramps were frequently seen 
in children with NMDs and often responded to massage, 
paracetamol, ibuprofen, a mechanical compression device 
(Flowtron®) or transcutaneous electrical nerve stimulation 
(TENS). A significant number of children had non-organic 
or psychosomatic pain.34,35
Cardiovascular
As cardiac involvement is common in children with 
NMDs, all patients had a baseline cardiovascular assessment 
at the time of diagnosis.36 Boys with DMD and teenagers 
with BMD had annual echocardiograms to check for early 
signs of cardiomyopathy. Regular electrocardiograms 
were recommended for patients with MD and Emery-
Dreifuss muscular dystrophy to detect conduction defects 
that may necessitate anti-arrhythmic drug therapy or a 
pacemaker.37,38 Once the left ventricular ejection fraction 
started to decrease significantly in DMD patients, treatment 
with a beta-adrenoceptor blocker (e.g. bisoprolol) and an 
angiotensin-converting enzyme inhibitor (e.g. perindopril) 
was commenced39,40 Occasionally, long-term use of 
oral steroids led to moderate hypertension. If this was 
suspected following one abnormal reading, the blood 
pressure was measured repeatedly on different days using 
a sphygmomanometer with a cuff covering at least 2/3 of 
the child’s upper arm. Antihypertensive therapy was rarely 
required and usually initiated by a pediatric nephrologist 
without stopping the steroids.41
Respiratory
Children with NMDs, particularly those with DMD and 
SMA, are prone to develop chest infections, which is due to 
their weak respiratory muscles and their reduced mobility. 
It was therefore recommended that they should have the 
pneumococcal and the seasonal influenza vaccines.42 Lower 
respiratory tract infections were treated aggressively with 
oral or intravenous antibiotics. At each clinic visit, the young 
patients’ lung function was measured using an electronic 
spirometer with a printer. If symptoms of nocturnal hypoxia 
and hypercapnia were reported, for instance headaches 
and tiredness in the morning, an overnight pulse oximetry 
study was arranged which allowed continuous recording of 
oxygen saturations and heart rate, and early recognition of 
desaturations.43,44 When a patient’s coughing capacity was 
significantly reduced, a mechanical insufflation/exsufflation 
device (CoughAssist®) was prescribed to help removing 
secretions from the lungs.45 A steady decline in the FVC 
(absolute and percent predicted) indicated the need for a 
referral to the home ventilation team and, usually in the 
second decade of life, initiation of non-invasive positive 
pressure ventilation (NIPPV) via a nasal mask, a face mask or 
a mouthpiece to prevent respiratory failure. A tracheostomy 
was rarely required.46,47
Gastrointestinal
At each consultation, a dietary history was obtained 
including appetite, length of meal times and difficulties with 
chewing and swallowing. If recurrent choking episodes were 
reported, the patient was referred to a specialist speech and 
language therapist for a formal feeding assessment and a 
videofluoroscopy study.48 Parents were advised to take their 
children for regular dental appointments to recognize caries 
and gingivitis early.49 The importance of a balanced, high-
fiber diet was emphasized to improve general well-being 
and facilitate regular bowel function. Constipation was fairly 
common and usually responded to lactulose, macrogols, 
senna or docusate sodium.50 Gastroesophageal reflux was 
treated with aluminum hydroxide and magnesium carbonate 
or ranitidine. Excessive weight gain was frequently observed 
in children receiving oral steroids, particularly those on 
prednisolone, who developed cushingoid features. Some 
young patients with a NMD did not show adequate weight 
gain despite input from a dietician and therefore required 
nasogastric tube feeding or a gastrostomy.51,52
Urogenital
Children with NMDs are prone to dehydration due to 
their restricted mobility, which can lead to renal impairment. 
Myoglobinuria is another complication of inherited 
myopathies and can result in renal failure, if untreated. 
The protein myoglobin is released from damaged muscle 
fibers and causes brown discoloration of the urine which 
tests positive for blood on dipstick analysis. Older children 
were advised to avoid excessive exercise and encouraged 
to drink plenty of fluids, particularly during the summer 
months.53-55 Nocturnal and diurnal enuresis was treated 
with desmopressin or oxybutynin in children who did not 
have associated global developmental delay.56 Symptoms 
of a urinary tract infection were investigated promptly and 
managed according to current guidelines.57
Conclusion
Although the timely management of medical problems 
had priority in the children followed up here, there were 
other issues such as education and social integration that 
contributed to the quality of life of the patients and their 
families. Most children with NMDs attended a nursery or 
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